Re: Additional Reports of Exempt Distribution

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports of Exempt Distribution

in response to

Re: Additional Reports of Exempt Distribution

Nextblockbuster

posted on Jul 22, 2023 11:48AM

As I see it, they buy new shares directly from the company because they don't trust the OTC.

Less trade liquidity in acquiring shares in the 10's of thousands of shares on the OTC.

Don the salesman may have something to do with it!

Koo (IMO)

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply